OXFORD IMMUNOTEC LIMITEDActive
Key figures
Ratios
2023Balance sheet structure
Filed accounts2023
| 2023 | |
|---|---|
| Turnover | 47,445 |
| Cash at bank and in hand | 7,370 |
| Total assets | 51,323 |
| Total liabilities | 77,557 |
| Net assets / total equity | 29,228 |
| Average number of employees | 179 |
A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.
Principal activity
Accounts 2023We are a global, diagnostics company focused on developing and commercialising proprietary tests for immunology and infectious disease by leveraging the technological, product development, manufacturing, quality, regulatory, and sales and marketing capabilities we have developed over our history. Our proprietary T-SPOT.TB test utilises our T-SPOT technology platform to test for tuberculosis, or TB, which is the leading cause of death from infectious disease worldwide.
As described in the company's latest filed accounts.
Summary: OXFORD IMMUNOTEC LIMITED
Company
OXFORD IMMUNOTEC LIMITED is a private limited company registered with Companies House under company number 04516079. It was incorporated on 21 Aug 2002. Its status is active. The registered office is in Abingdon (OX14). Its nature of business (SIC 2007) is manufacture of pharmaceutical preparations (21200), other professional, scientific and technical activities n.e.c. (74909).
Accounts
The latest accounts in the database are for 2023 (period ending 31 Dec 2023); the company files full accounts. Turnover was £47,445. Net assets were £29,228. Cash at bank and in hand was £7,370. Total assets were £51,323 and total liabilities £77,557. The company had an average of 179 employees.
Control and charges
One person with significant control is registered.
Filing deadlines
The next accounts are due by 31 Dec 2026. The next confirmation statement is due by 28 Aug 2027.